Exploring Immune Data from Evaxion's Phase 2 Trial
In a remarkable development, Evaxion A/S (NASDAQ: EVAX), a pioneering clinical-stage TechBio company, recently presented significant new data regarding its personalized cancer vaccine, EVX-01. This data was shared at the Society for Immunotherapy of Cancer (SITC) 2025 Annual Meeting. The unveiling of this data adds to the robust efficacy profile already established through the previous presentation of two-year clinical outcomes from the same phase 2 trial.
AI-Powered Vaccine for Cancer Treatment
EVX-01, developed using Evaxion's innovative AI-Immunology™ platform, aims to address a crucial aspect of cancer treatment by targeting neoantigens—unique proteins formed due to mutations that exist in tumors. The latest findings share exciting biomarker and immune response data derived from the phase 2 clinical trial where EVX-01 was combined with the anti-PD-1 therapy, KEYTRUDA® (pembrolizumab), from MSD (Merck & Co., Inc.). This therapy approach is notably significant for patients with advanced melanoma, a challenging and aggressive form of skin cancer.
Insights from Patient Blood Analysis
As part of the trial, longitudinal blood samples were obtained from patients at different treatment stages to analyze immune system changes attributed to the vaccine. The focus of this analysis included distinct T-cell subsets, which helped illuminate the immune responses triggered by EVX-01. Notably, in certain patient groups, positive clinical outcomes correlated with the swift generation and sustained presence of EVX-01-specific T-cells during the trial.
Encouragement from the Scientific Community
Birgitte Rønø, CSO and interim CEO of Evaxion, expressed enthusiasm about presenting these insightful data at the SITC conference, highlighting the ongoing commitment to enhancing EVX-01's existing strong data profile. The recent two-year efficacy data presentation at the European Society for Medical Oncology 2025 congress has also sparked notable interest among medical professionals in the potential of EVX-01.
Overview of Evaxion and Its Vision
Evaxion is dedicated to transforming cancer treatments through groundbreaking technologies rooted in AI. By leveraging its proprietary AI-Immunology™ platform, the company is at the forefront of developing novel immunotherapies to combat various illnesses, including cancer and serious infectious diseases. With a promising oncology pipeline of advanced personalized vaccines, Evaxion is poised to make significant contributions to patient care and redefine treatment paradigms.
Contact Information
If you're looking to learn more about Evaxion and its remarkable advancements in the field of immunotherapies, you can reach out to:
Evaxion A/S
Mads Kronborg
Vice President, Investor Relations & Communication
+45 53 54 82 96
mak@evaxion.ai
Frequently Asked Questions
What is EVX-01?
EVX-01 is a personalized cancer vaccine developed by Evaxion, designed to generate immune responses against cancer-specific neoantigens.
What recent data was presented at the SITC?
Evaxion presented new biomarker and immune response data from a phase 2 trial showing EVX-01's efficacy in combination with KEYTRUDA®.
What role does AI play in Evaxion's developments?
Evaxion utilizes its AI-Immunology™ platform to develop innovative vaccines by decoding immune system responses to target cancer effectively.
How was the immune response data obtained?
Researchers analyzed longitudinal patient blood samples before, during, and after treatment to assess the immune responses resulting from EVX-01.
What is the significance of the collaboration with Merck's KEYTRUDA®?
The collaboration enhances the therapeutic potential of EVX-01 by evaluating its effect when combined with an established anti-PD-1 therapy, providing further evidence of its efficacy in melanoma treatment.
